In MAPK inhibitor- adapted melanoma cells, ITCH can downregulate the immunosuppressor, PD-L1 levels via ubiquitin-directed lysosomal degradation, which can enhance tumor rejection by activating cytolytic CD8+ T cells27. Here, CD274 is linked to neoplasm.